EMPA-REG OUTCOME: Consistent reduction in risk of cardiovascular outcomes and mortality with empagliflozin irrespective of sulphonylurea use at baseline

被引：0
|
作者：
Inzucchi, S. E. [1 ]
George, J. T. [2 ]
Fitchett, D. [3 ]
Mattheus, M. [2 ]
Janista, C. [2 ]
Zinman, B. [4 ]
机构：
[1] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [31] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Toural, E.
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. -J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2016, 59 : S539 - S540
  • [32] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
  • [33] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    Lund, S. S.
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Fitchett, D.
    DIABETOLOGIA, 2018, 61 : S324 - S325
  • [34] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
    Bernard Zinman
    Silvio E. Inzucchi
    Christoph Wanner
    Uwe Hehnke
    Jyothis T. George
    Odd Erik Johansen
    David Fitchett
    Diabetologia, 2018, 61 : 1522 - 1527
  • [35] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
    McGuire, D. K.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    George, J. T.
    Elsasser, U.
    Woerle, H. J.
    Lund, S. S.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1091 - 1091
  • [36] Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
    Suissa, Samy
    DIABETES CARE, 2018, 41 (02) : 219 - 223
  • [37] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
    Odutayo, Ayodele
    Zinman, Bernard
    Wanner, Christoph
    Zwiener, Isabella
    Lund, Soren S.
    Hantel, Stefan
    Fitchett, David
    Udell, Jacob A.
    CJC OPEN, 2024, 6 (07) : 868 - 875
  • [38] Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    George, Jyothis
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wanner, Christoph
    Hauske, Sibylle
    DIABETES, 2019, 68
  • [39] The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
    Neeland, Ian J.
    Eliasson, Bjorn
    Kasai, Takatoshi
    Marx, Nikolaus
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Zwiener, Isabella
    Wojeck, Brian S.
    Yaggi, Henry K.
    Johansen, Odd Erik
    DIABETES CARE, 2020, 43 (12) : 3007 - 3015
  • [40] Cardiovascular outcomes according to LDL cholesterol levels in EMPA-REG OUTCOME
    Langslet, G.
    Zinman, B.
    Wanner, C.
    Hantel, S.
    Espadero, R. -M.
    Johansen, O. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
12345